CEO
“This year we have set three goals that represent the progress in our go-to-market plan: introducing IndiTreat® in 30 hospitals across
With the full focus and effort of our teams, we have made very good progress in the first quarter of 2022. We recruited 8 hospitals for the IGNITE program and are in advanced conversations with several more, we launched IndiTreat® Explore to identify drugs that could be used “off label” in third line mCRC patients, and we added 3 new countries –
We are confident that we are on track to achieve our goals for 2022 despite the turbulent economic and political situation in
FINANCIAL HIGHLIGHTS
The financial development is in line with our plans and expectations, and with a cash position of
2022 (2022-01-01 until 2022-03-31) – the group
Net turnover for the period was 0 KSEK (0 KSEK).
Other operating income was 434 KSEK (3 850 KSEK)
The result before tax was -7 897 KSEK (-1 835 KSEK)
The result per share* was -
The solidity** was 96 % (94 %).
The cash and bank were 63 348 KSEK (53 991 KSEK).
*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in Q1 2022: 17 513 876 shares. Total number of shares in
**Equity ratio: Shareholder’s equity divided by total capital.
Significant events during the first quarter 2022
January:
New Institutional shareholder.
New Distributor for IndiTreat® in
February:
Announces a reorganization to an even stronger distributor focus.
Publising Q4 2021 and a virtual live session presenting the Q4 2021 report
March:
2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022
Significant events after the period
April:
Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program.
Notice of annual general meeting of
May:
2cureX publishes the annual report for the fiscal year 2021.
Redeye research interview with 2cureX CEO,
2cureX appoints
2cureX presents IndiTreat® clinical results at the
IGNITE update: Eight hospitals have been enrolled in the program.
Presenting Dr.
Three IndiTreat® posters have been accepted at ESMO-GI 2022
© Modular Finance, source